Log in to your Inderes Free account to see all free content on this page.

Intervacc

1.14 SEK

-0.70%

Less than 1K followers

IVACC

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Income statement

Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Intervacc

2019202020212022202320242025
Revenue12.14.85.29.78.011.820.1
growth-%-60.6 %9.6 %84.7 %-17.1 %47.0 %70.4 %
EBITDA-21.7-19.5-23.2-43.6-69.0-58.8-64.9
EBIT-27.8-25.7-29.4-64.4-93.6-77.3-83.5
Profit before taxes-27.9-25.6-29.4-64.2-91.5-75.5-80.8
Net income-27.9-25.6-29.4-64.2-102.9-75.5-80.8
EPS-0.53-0.38-0.44-0.95-1.45-0.86-0.27
Dividend0.000.000.000.000.000.000.00
Dividend ratio-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %-0.0 %
Login required

This content is only available for logged in users

Profitability and return on capital

2019202020212022202320242025
EBITDA-%-178.7 %-408.0 %-443.4 %-450.0 %-860.1 %-498.3 %-323.1 %
EBIT-%-229.4 %-537.2 %-560.8 %-665.4 %-1,166.8 %-655.5 %-415.7 %
ROE-12.7 %-7.6 %-9.5 %-25.6 %-43.2 %-46.5 %-29.4 %
ROI-11.8 %-7.2 %-8.9 %-24.2 %-39.6 %-40.3 %-27.4 %
Login required

This content is only available for logged in users